We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
TIMP4 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
124.8
Number of samples
141
Samples
Sample
Description
TPM
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
666.5
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
572.1
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
510.8
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
491.8
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
431.3
TCGA-02-0047-01A
0 years, male, white, stage:'--, dead, 448 days
427.0
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
416.7
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
410.9
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
385.8
TCGA-06-0178-01A
0 years, male, white, stage:'--, dead, 2681 days
372.2
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
325.0
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
324.9
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
294.1
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
292.8
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
288.6
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
269.1
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
267.8
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
262.5
TCGA-14-1825-01A
0 years, male, white, stage:'--, dead, 232 days
260.5
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
259.4
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
230.1
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
213.6
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
203.3
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
198.5
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
198.3
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
194.2
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
192.3
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
191.4
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
180.7
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
180.1
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
176.7
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
163.0
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
159.3
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
151.2
TCGA-27-1831-01A
0 years, male, white, stage:'--, dead, 505 days
150.5
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
148.0
TCGA-41-2572-01A
0 years, male, white, stage:'--, dead, 406 days
140.9
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
137.4
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
136.0
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
135.8
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
130.9
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
126.8
TCGA-06-0743-01A
0 years, male, white, stage:'--, dead, 803 days
125.8
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
123.3
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
122.9
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
122.4
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
121.6
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
118.1
TCGA-06-5859-01A
0 years, male, white, stage:'--, alive, 139 days
116.6
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
116.3
TCGA-06-0219-01A
0 years, male, white, stage:'--, dead, 22 days
113.6
TCGA-26-1442-01A
0 years, male, white, stage:'--, alive, 953 days
112.8
TCGA-19-2624-01A
0 years, male, white, stage:'--, dead, 5 days
111.7
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
110.7
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
110.6
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
110.3
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
103.7
TCGA-06-1804-01A
0 years, female, white, stage:'--, dead, 414 days
99.3
TCGA-28-2514-01A
0 years, male, asian, stage:'--, alive, 160 days
99.2
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
97.4
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
96.0
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
95.0
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
93.4
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
91.9
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
90.5
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
90.3
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
87.5
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
83.6
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
83.3
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
82.4
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
82.3
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
80.1
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
80.1
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
80.0
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
78.2
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
77.7
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
77.1
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
76.8
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
75.7
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
75.5
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
74.0
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
72.6
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
72.6
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
71.2
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
71.0
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
68.5
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
65.5
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
64.0
TCGA-06-0158-01A
0 years, male, white, stage:'--, dead, 329 days
63.9
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
63.0
TCGA-19-1390-01A
0 years, female, white, stage:'--, dead, 772 days
62.9
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
62.5
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
60.5
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
59.0
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
58.7
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
58.5
TCGA-26-5135-01A
0 years, female, white, stage:'--, dead, 270 days
58.2
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
58.2
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
55.7
TCGA-12-0618-01A
0 years, male, white, stage:'--, dead, 395 days
53.8
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
52.6
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
52.4
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
49.4
TCGA-06-0129-01A
0 years, male, asian, stage:'--, dead, 1024 days
48.2
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
48.1
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
46.8
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
45.4
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
45.3
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
45.2
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
45.1
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
44.8
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
44.4
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
44.4
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
43.7
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
42.7
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
39.3
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
36.8
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
36.0
TCGA-41-2571-01A
0 years, male, white, stage:'--, dead, 26 days
34.9
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
34.2
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
34.1
TCGA-06-2562-01A
0 years, male, white, stage:'--, dead, 382 days
34.0
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
31.8
TCGA-06-0747-01A
0 years, male, white, stage:'--, dead, 82 days
31.7
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
31.3
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
30.5
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
30.0
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
29.8
TCGA-26-5134-01A
0 years, male, white, stage:'--, alive, 167 days
26.0
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
25.8
TCGA-27-2524-01A
0 years, male, white, stage:'--, dead, 231 days
23.4
TCGA-06-0139-01A
0 years, male, white, stage:'--, dead, 362 days
22.2
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
22.0
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
18.9
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
18.6
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
11.9
TCGA-14-0871-01A
0 years, female, white, stage:'--, dead, 880 days
11.7
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
9.1
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
8.4
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
6.3
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
TIMP4 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
43.9
Number of samples
58
Samples
Sample
Description
TPM
AK079
N, NA, stage:NA, dead, 210 days
160.9
AK049
N, NA, stage:NA, dead, 180 days
150.9
AK071
N, NA, stage:NA, dead, 540 days
117.1
AK076
N, NA, stage:NA, alive, 660 days
115.6
AK231
N, NA, stage:NA, dead, 240 days
97.7
AK199
N, NA, stage:NA, alive, 1860 days
87.8
AK006
N, NA, stage:NA, dead, 360 days
84.3
AK002
N, NA, stage:NA, dead, 570 days
81.0
AK102
N, NA, stage:NA, alive, 1740 days
74.3
AK183
N, NA, stage:NA, alive, 360 days
74.0
AK091
N, NA, stage:NA, dead, 210 days
71.6
AK213
N, NA, stage:NA, alive, 2010 days
65.0
AK149
N, NA, stage:NA, dead, 420 days
64.1
AK051
N, NA, stage:NA, dead, 360 days
62.5
AK072
N, NA, stage:NA, dead, 150 days
57.0
AK003
N, NA, stage:NA, dead, 600 days
56.5
AK098
N, NA, stage:NA, dead, 660 days
56.0
AK088
N, NA, stage:NA, dead, 360 days
55.2
AK100
N, NA, stage:NA, alive, 960 days
54.5
AK085
N, NA, stage:NA, alive, 660 days
52.3
AK156
N, NA, stage:NA, dead, 330 days
50.8
AK178
N, NA, stage:NA, dead, 240 days
47.6
AK124
N, NA, stage:NA, alive, 1920 days
45.7
AK167
N, NA, stage:NA, dead, 180 days
41.1
AK068
N, NA, stage:NA, alive, 360 days
36.9
AK030
N, NA, stage:NA, dead, 120 days
36.5
AK035
N, NA, stage:NA, dead, 210 days
35.6
AK139
N, NA, stage:NA, dead, 270 days
34.9
AK218
N, NA, stage:NA, dead, 180 days
33.4
AK227
N, NA, stage:NA, alive, 300 days
32.8
AK236
N, NA, stage:NA, dead, 360 days
31.9
AK188
N, NA, stage:NA, alive, 420 days
29.7
AK055
N, NA, stage:NA, dead, 240 days
28.5
AK153
N, NA, stage:NA, dead, 240 days
28.4
AK173
N, NA, stage:NA, dead, 180 days
28.0
AK043
N, NA, stage:NA, alive, 660 days
27.9
AK103
N, NA, stage:NA, alive, 1320 days
27.8
AK158
N, NA, stage:NA, dead, 360 days
26.0
AK133
N, NA, stage:NA, dead, 360 days
25.7
AK195
N, NA, stage:NA, dead, 390 days
24.8
AK142
N, NA, stage:NA, alive, 90 days
22.8
AK216
N, NA, stage:NA, dead, 360 days
22.2
AK123
N, NA, stage:NA, dead, 180 days
20.7
AK066
N, NA, stage:NA, alive, 960 days
19.6
AK134
N, NA, stage:NA, dead, 360 days
18.9
AK185
N, NA, stage:NA, alive, 330 days
18.7
AK015
N, NA, stage:NA, alive, 720 days
18.6
AK099
N, NA, stage:NA, dead, 420 days
18.5
AK074
N, NA, stage:NA, alive, 300 days
13.7
AK081
N, NA, stage:NA, dead, 180 days
11.8
AK089
N, NA, stage:NA, dead, 330 days
11.1
AK005
N, NA, stage:NA, dead, 240 days
10.2
AK053
N, NA, stage:NA, dead, 300 days
8.8
AK117
N, NA, stage:NA, dead, 210 days
8.6
AK041
N, NA, stage:NA, alive, 810 days
5.4
AK165
N, NA, stage:NA, alive, 360 days
5.3
AK226
N, NA, stage:NA, dead, 360 days
2.0
AK205
N, NA, stage:NA, dead, 120 days
2.0
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0206110003
Tumor
1.8
CPT0204360003
Normal
1.2
CPT0219080004
Tumor
1.0
CPT0171580008
Tumor
0.7
CPT0205570003
Tumor
0.7
CPT0217710008
Tumor
0.6
CPT0162100003
Tumor
0.6
CPT0087680003
Tumor
0.6
CPT0064890003
Tumor
0.5
CPT0093550003
Tumor
0.5
CPT0168380003
Tumor
0.5
CPT0224600003
Tumor
0.5
CPT0217100003
Tumor
0.4
CPT0079790003
Tumor
0.4
CPT0189650004
Tumor
0.4
CPT0221180003
Tumor
0.4
CPT0093450003
Tumor
0.4
CPT0093510003
Tumor
0.4
CPT0217880003
Tumor
0.4
CPT0205450004
Tumor
0.4
CPT0078580003
Tumor
0.3
CPT0216920008
Tumor
0.3
CPT0228220003
Tumor
0.2
CPT0217060003
Tumor
0.2
CPT0189460003
Tumor
0.2
CPT0217190003
Tumor
0.2
CPT0189750004
Tumor
0.2
CPT0189570004
Tumor
0.2
CPT0205670004
Tumor
0.2
CPT0087950003
Tumor
0.2
CPT0218960004
Tumor
0.2
CPT0218770003
Tumor
0.2
CPT0089150003
Tumor
0.1
CPT0127420003
Tumor
0.1
CPT0218690004
Tumor
0.1
CPT0199770003
Tumor
0.1
CPT0206330003
Tumor
0.1
CPT0225760003
Tumor
0.1
CPT0224390004
Tumor
0.1
CPT0204400003
Normal
0.1
CPT0168270003
Tumor
0.1
CPT0204410003
Normal
0.1
CPT0196850003
Tumor
0.1
CPT0167970003
Tumor
0.1
CPT0087570003
Tumor
0.1
CPT0064650003
Tumor
0.0
CPT0218830004
Tumor
0.0
CPT0206230003
Tumor
0.0
CPT0167860004
Tumor
0.0
CPT0127480003
Tumor
0.0
CPT0125510003
Tumor
0.0
CPT0189250003
Tumor
0.0
CPT0206880003
Tumor
-0.1
CPT0205890003
Tumor
-0.1
CPT0189850004
Tumor
-0.1
CPT0224540004
Tumor
-0.1
CPT0167750004
Tumor
-0.1
CPT0168720003
Tumor
-0.1
CPT0002410011
Tumor
-0.1
CPT0123530003
Tumor
-0.2
CPT0167530003
Tumor
-0.2
CPT0175060003
Tumor
-0.2
CPT0204390003
Normal
-0.2
CPT0204420003
Normal
-0.2
CPT0206000004
Tumor
-0.3
CPT0168480003
Tumor
-0.3
CPT0218330004
Tumor
-0.3
CPT0207030003
Tumor
-0.3
CPT0182580003
Tumor
-0.3
CPT0205780003
Tumor
-0.4
CPT0204380003
Normal
-0.4
CPT0218890004
Tumor
-0.4
CPT0167640003
Tumor
-0.4
CPT0204350003
Normal
-0.4
CPT0168830003
Tumor
-0.4
CPT0092440003
Tumor
-0.5
CPT0224330003
Tumor
-0.5
CPT0104330003
Tumor
-0.6
CPT0104220003
Tumor
-0.6
CPT0206560003
Tumor
-0.6
CPT0190360004
Tumor
-0.6
CPT0071100003
Tumor
-0.6
CPT0161730003
Tumor
-0.7
CPT0206670004
Tumor
-0.8
CPT0190240004
Tumor
-0.8
CPT0204370003
Normal
-0.8
CPT0162140003
Tumor
-0.9
CPT0182550003
Tumor
-0.9
CPT0208980003
Tumor
-1.0
CPT0209440003
Tumor
-1.1
CPT0186100003
Tumor
N/A
CPT0201710003
Tumor
N/A
CPT0093590003
Tumor
N/A
CPT0218670003
Tumor
N/A
CPT0204340003
Normal
N/A
CPT0217430008
Tumor
N/A
CPT0217000004
Tumor
N/A
CPT0162020003
Tumor
N/A
CPT0206780003
Tumor
N/A
CPT0182500003
Tumor
N/A
CPT0125220003
Tumor
N/A
CPT0087730003
Tumor
N/A
CPT0168590003
Tumor
N/A
CPT0125570003
Tumor
N/A
CPT0168080003
Tumor
N/A
CPT0225730003
Tumor
N/A
CPT0093360003
Tumor
N/A
CPT0206450003
Tumor
N/A
CPT0207090003
Tumor
N/A
CPT0204330003
Normal
N/A
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.